Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nutra Pharma Corp (NPHC)

Nutra Pharma Corp (NPHC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Nutra Pharma Corp 1537 NW 65th Ave Plantation FL 33313 USA

www.nutrapharma.com P: 954-509-0911

Description:

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company operates through its subsidiaries and carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma currently offers several drug products for sale for the treatment of pain: Cobroxin, the over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, the non-narcotic and non-addictive treatment for severe (Stage 3) pain. In addition, the Company is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases. Nutra Pharma Corporation is based in Boca Raton, Florida.

Key Statistics

Overview:

Market Capitalization, $K 706
Enterprise Value, $K 8,376
Shares Outstanding, K 7,064,740
Annual Sales, $ 100 K
Annual Net Income, $ -13,100 K
Last Quarter Sales, $ 110 K
Last Quarter Net Income, $ 580 K
EBIT, $ -1,390 K
EBITDA, $ -1,010 K
60-Month Beta 0.00
% of Insider Shareholders 61.50%
% of Institutional Shareholders 0.00%
Float, K 2,719,925
% Float 38.50%
Short Volume Ratio 0.02

Growth:

1-Year Return 0.00%
3-Year Return -83.33%
5-Year Return -75.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 10/02/23
Earnings Per Share ttm 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-40 on 05/19/15

NPHC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -13,100.00%
Debt/Equity -0.51
Price/Sales 2.82
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.00
Interest Coverage -25.20
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar